Aucun commentaire disponible.
Nanjing Hanxin Pharmaceutical Technology Co., Ltd., restructured in 2021 from the China R&D Center of US-based Amphastar Pharmaceuticals, Inc. with registered capital of RMB 183 million, stands as a fast-growing biopharmaceutical leader specializing in peptides, proteins and polysaccharides.
Laissez votre note & commentaire